4.7 Article

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Q. P. Janssen et al.

Summary: The PREOPANC-2 trial compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer, aiming to provide evidence for the optimal neoadjuvant treatment choice in these patients.

BMC CANCER (2021)

Article Oncology

Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study

Stijn van Roessel et al.

Summary: This study revealed a rate of 16% clinically relevant misdiagnoses in patients undergoing pancreatoduodenectomy, emphasizing the importance of accurate preoperative diagnosis in determining appropriate treatment strategies. The accuracy of preoperative diagnosis for pancreatic cancer and other periampullary cancers was found to be relatively low, with potential implications for the administration of neoadjuvant chemotherapy.
Article Oncology

Cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Article Medicine, General & Internal

Pancreatic cancer

Jonathan D Mizrahi et al.

LANCET (2020)

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial

Helmut Oettle et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)